

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

**SUPPLEMENTAL FRAMEWORK AGREEMENT
OF A POSSIBLE ACQUISITION**

This announcement is made by Touyun Biotech Group Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcement of the Company dated 23 November 2021 (the “**Announcement**”) in relation to, among other things, a Possible Acquisition. Capitalised terms used in this announcement shall have the same meaning as those defined in the Announcement unless otherwise defined.

Due to the COVID-19 outbreak of the omicron variant, the Purchaser and the Vendors have been unable to enter into a Formal Agreement as (i) due diligence on the Target Company has not yet been completed to the Purchaser’s satisfaction; and (ii) a valuation of the Target Company has not yet been determined. As additional time is required for the due diligence on the Target Company as well as for negotiations on the terms and conditions of the Formal Agreement, the Purchaser entered into a supplemental framework agreement (the “**Supplemental Framework Agreement**”) with the Vendors on 22 April 2022 and agreed to extend the exclusivity period for the Possible Acquisition, and the period to finalise the detailed terms and conditions and execution of the Formal Agreement to 22 October 2022 or such later date as the Purchaser and Vendors may otherwise agree in writing.

Save for the above, all other terms and conditions of the Framework Agreement shall remain unchanged and shall continue in full force and effect.

The final terms of the Formal Agreement in respect of the Possible Acquisition are subject to further negotiations between the parties and have yet to be finalised and may therefore deviate from those set out in the Framework Agreement.

The Framework Agreement (as amended and supplemented by the Supplemental Framework Agreement) is not legally binding. The Possible Acquisition may or may not proceed. Further announcement(s) in respect of the Possible Acquisition will be made by the Company as and when appropriate. Shareholders and possible investors of the Company are reminded to exercise caution when dealing in the Shares.

By Order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 22 April 2022

As at the date of this announcement, the Board comprised the following Directors:

Executive Directors:

Mr. Wang Liang (*Chairman*)
Mr. Du Dong

Non-executive Directors:

Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele
Mr. Jia Wenjie

Independent Non-executive Directors:

Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen
Mr. Hu Guohua